AstraZeneca shares sink 8% after $39 billion Alexion buyout By Reuters



© Reuters. FILE PHOTO: The logo of AstraZeneca is seen on medication packages in a pharmacy in London

(Reuters) – Shares of AstraZeneca (NASDAQ:) fell 8% early on Monday, hit by doubts about the British firm’s strategy and speculation of a rival bid after it announced the $39 billion purchase of Alexion Pharmaceuticals (NASDAQ:) over the weekend.

Chief Executive Officer Pascal Soriot had told reporters on Saturday that the deal, a bet on rare-disease and immunology drugs, was the result of exclusive talks and no competitive bidder was involved.

The move also helps AstraZeneca, which is also working on a COVID-19 vaccine, diversify from its fast-growing cancer business.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.





Source link

Leave a Reply

Your email address will not be published. Required fields are marked *